News
Hand holding a pen following the peaks and troughs of a graph on screen

BioAge's $100m IPO, and other biotech financings

Our round-up of financings in the biotech sector this week is led by BioAge Lab's filing of an initial public offering (IPO), with a placeholder target of $100 million, plus sizeable privat

Sales & Marketing

Digital

Market Access

Newsletters and Deep Dive
digital magazine

Oncology

News
MSD hits a hurdle with its LAG-3 programme

MSD hits a hurdle with its LAG-3 programme

MSD's combination of PD-1 inhibitor Keytruda and experimental LAG-3 inhibitor favezelimab has failed a phase 3 trial in patients with previously treated PD-L1-positive microsatellite stable

Patients

R&D

Partner Content

R&D
9th CDD For Biologics Summit 2024 banner
Partner Content

9th CDD For Biologics Summit 2024

Integrate Computational Biology, Generative AI & Machine Learning to Revolutionize Biologics Drug Discovery & Development